What is the appropriate evaluation and treatment for heavy menstrual bleeding (menorrhagia)?

Evaluation and Treatment for Heavy Menstrual Bleeding

Begin evaluation with a pregnancy test, complete blood count with ferritin, thyroid-stimulating hormone, and prolactin levels, followed by transvaginal ultrasound to identify structural causes—then initiate first-line treatment with either the levonorgestrel-releasing intrauterine device (52 μg/d) or combined hormonal contraceptives based on contraceptive needs. 1

Initial Evaluation Algorithm

Essential Laboratory Testing

All reproductive-age women presenting with heavy menstrual bleeding require:

• Pregnancy test (beta-hCG) - mandatory first step 2
• Complete blood count to assess for anemia 3
• Serum ferritin - critical for detecting iron deficiency even before anemia develops 3
• Thyroid-stimulating hormone and prolactin levels to rule out endocrine causes 1

Bleeding Disorder Screening

Screen for underlying bleeding disorders when patients report:

• Clots ≥1 inch diameter
• "Flooding" (changing pad/tampon more frequently than hourly)
• Personal or family history of bleeding symptoms
• Low ferritin levels 4

Up to 20% of women with heavy menstrual bleeding have an underlying inherited bleeding disorder, most commonly von Willebrand disease 5, 6. Use validated screening tools like PBAC (Pictorial Blood Assessment Chart), Philipp tool, or self-BAT to identify who needs hematology referral 7.

Imaging Strategy

Transvaginal ultrasound is the primary imaging modality to evaluate for structural causes 1, 8:

• Identifies polyps, adenomyosis, leiomyomas, and endometrial pathology
• Saline infusion sonohysterography has 96-100% sensitivity for intracavitary lesions and provides superior endometrial assessment 1
• Reserve MRI for cases where ultrasound cannot adequately visualize the endometrium due to fibroids or adenomyosis 8

Endometrial Sampling Indications

Perform endometrial biopsy (preferred over dilation and curettage due to lower invasiveness, safety, and cost) in women with 1:

• Age >45 years
• Failed medical treatment
• Risk factors for endometrial hyperplasia or cancer
• Persistent intermenstrual bleeding

Common pitfall: Endometrial biopsy sensitivity varies with lesion characteristics—focal lesions like polyps may be missed. If medical treatment fails despite negative biopsy, proceed to hysteroscopy for direct visualization 1.

Treatment Algorithm

First-Line Medical Management

For women desiring contraception or willing to use hormonal therapy:

• Levonorgestrel-releasing IUD (52 μg/d) - most effective medical option, achieving 71-95% reduction in menstrual blood loss, comparable to endometrial ablation efficacy 2, 9
• Combined hormonal contraceptives (oral, patch, or ring) - reduce bleeding symptoms effectively 1, 9

For women declining hormonal therapy:

• Tranexamic acid - nonhormonal antifibrinolytic agent that reduces menstrual blood loss 9, 6
• NSAIDs (e.g., mefenamic acid) - reduce bleeding and provide pain relief 9

Critical caveat: Avoid tranexamic acid and NSAIDs in women with cardiovascular disease or history of spontaneous coronary artery dissection due to thrombosis and MI risk 2.

Second-Line Medical Management

When first-line treatments fail or are contraindicated:

• GnRH agonists (leuprolide acetate) or GnRH antagonists (elagolix, relugolix) - reduce bleeding and fibroid volume by 30-50% 9
• Use lowest effective dose with add-back estrogen-progestin therapy to mitigate hypoestrogenic effects (hot flashes, bone loss) 9
• Cyclic oral progestins - reduce bleeding by 87%, though less effective than levonorgestrel IUD 2

Acute Heavy Bleeding Management

For hemodynamically unstable patients or bleeding saturating pad/tampon hourly for ≥4 hours:

1. Assess orthostatic vital signs 3
2. High-dose oral or injectable progestins for short-term control 2
3. Tranexamic acid (oral or IV) or aminocaproic acid for hemostatic effect 3
4. Consider examination under anesthesia if bleeding persists despite medical therapy 3

Lower hemoglobin levels, emergency department presentation, and multiple ER visits predict need for high-dose hormonal therapy 10.

Surgical Options

When medical management fails, is contraindicated, or patient has significant intracavitary lesions:

Hysteroscopic myomectomy - procedure of choice for pedunculated submucosal fibroids <5 cm, with equivalent symptom improvement to more invasive approaches 9

Endometrial ablation (second-generation techniques: thermal balloon, microwave, radiofrequency):

• Greater long-term efficacy than oral medical treatment 2
• Shorter hospitalization and faster recovery than hysterectomy 9
• Not first-line but appropriate when medical therapy fails 1
• Counsel about potential complications: Asherman syndrome, cervical stenosis, delayed endometrial cancer diagnosis 1

Hysterectomy - definitive treatment providing complete resolution of symptoms, reserved for failed medical/ablative therapy or when less invasive options are unsuitable 9

Special Populations

Women with bleeding disorders:

• Coordinate care with hematology 3
• Levonorgestrel IUD is safe and highly effective 5
• DDAVP for von Willebrand disease during menses 6
• Factor concentrate administration may be needed for severe inherited bleeding disorders 6

Women on antiplatelet therapy:

• Reassess indication for ongoing antiplatelet therapy first 2
• Levonorgestrel IUD preferred (minimal systemic absorption) 2
• Avoid NSAIDs and tranexamic acid 2

Long-Term Outcomes

At 10-year follow-up, only 29% of women required surgical intervention (17% hysterectomy, 13% endometrial ablation), and 43% continued using levonorgestrel IUD, demonstrating that medical management initiated in primary care achieves sustained symptom control with low surgical rates 11.